期刊文献+

生理药代动力学模型的特征及其国内外研究进展 被引量:6

Characteristics and Research Progress of Physiologically Based Pharmacokinetic Model
原文传递
导出
摘要 介绍生理药代动力学(PBPK)模型的特征及其研究现状。通过Pubmed检索工具,查询国内外相关文献21篇,对PBPK模型的构建、模型特征和应用现状进行了文献整理和分析。目前PBPK模型已经广泛应用于有毒化合物的安全性评价、药物代谢过程研究、代谢酶和转运蛋白对药物代谢的影响、药物-药物相互作用以及新药的研发过程等研究之中。尽管PBPK模型有很多优势,获得了令人鼓舞的评价结果,但其构建需要数学和计算机的支持以及系统生物学、药物化学、药理学和数学、统计学等多学科专业人员合作,做进一步的探索和完善。 Introduce the characteristic and research status for physiologically based pharmacokinetic model(PBPK).This article systemized and analysed the construction,features and application status of the PBPK model by reference 21 literatures from Pubmed.Currently,PBPK model has been widely used in the safety evaluation of toxic compounds,drug metabolism research,the influence of the drug by the enzymes and transport proteins,drug-drug interaction,and the research and development of new drugs.Although PBPK model has many advantages,and won the most encouraged evaluate results,but it need support of mathematics and computers,and cooperate of a multidisciplinary professionals,which including systems biology,medicine chemistry,pharmacology and statistic,etc,to further exploration and perfect.
出处 《中国实验方剂学杂志》 CAS 北大核心 2012年第1期247-250,共4页 Chinese Journal of Experimental Traditional Medical Formulae
基金 国家自然科学基金项目(81001684) 科技部"十一五"重大新药创制项目(2010ZX09102-216) 科技部重大新药创制专项(2008zx09312-012) 中国中医科学院广安门医院所级科研基金课题(81370)
关键词 生理药代动力学 药物相互作用 生理药代动力学/药理学 PBPK model drug-drug interaction PBPK/PD
  • 相关文献

参考文献21

  • 1Nestorov I. Whole body pharmacokinetic models [J].Clin Pharmacokinet, 2003,42 (10) : 883.
  • 2Neatorv I. whole-body physiologically based pharmacokinetic models[ J]. Expert Opin Drug Metab Toxicol, 2007,3 (2) : 235.
  • 3Clewell R A, Clewell H J. Development and specification of physiologically based pharmacokinetic models for use in risk assessment [ J]. Regul Toxieol Pharmacol, 2008,50( 1 ) : 129.
  • 4Pang K S, Durk M R. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion [ J ]. J Pharmacokinet Pharmacodyn, 2010,37(6): 591.
  • 5Teitelbaum Z, Lave T, Freijer J, et al. Risk assessment in extrapolation of pharmaco- kinetics from preclinical data to humans [ J]. Clin Pharmacokinet, 2010, 49 (9) :619.
  • 6Chiu W A, White P. Steady-state solutions to PBPK models and their applications to risk assessment I: route-to-route extrapolation of volatile chemicals [ J ]. Risk Anal, 2006,26(3) : 769.
  • 7Simmons J E, Evans M V, Boyes W K. Moving from external exposure concentration to internal dose: duration extrapolation based on physiologically based pharmacokinetic derived estimates of internal dose [ J ]. J Toxicol Environ Health A, 2005,68(11/12) :927.
  • 8Yuan L G, Luo X Y, Zhu L X, et al. A physiologically based pharmacokinetic model for valnemulin in rats and extrapolation to pigs[ J]. J Vet Pharmacol Ther, 2011, 34(3) :224.
  • 9Yoon M, Schroeter J D, Nong A, et al. Physiologically based pharmacokinetic modeling of fetal and neonatal manganese exposure in humans: describing manganese homeostasis during development [ J ]. Toxicol Sci, 2011, 122(2) : 297.
  • 10Fan J, Chen S, Chow E C, et al. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism [ J ]. Curr Drug Metab, 2010,11 (9) :743.

同被引文献42

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部